GSE157904 3 V 1 DOXORUBICIN MOUSE DN (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE157904 3 V 1 DOXORUBICIN MOUSE DN.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE157904 3 V 1 DOXORUBICIN MOUSE DN.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE157904 3 V 1 DOXORUBICIN MOUSE DN.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE157904 3 V 1 DOXORUBICIN MOUSE DN.

Results found

Linked to

 

Label

Description

 

Gene

transmembrane protein 276

Gene

CXXC repeat containing interactor of PDZ3 domain

Gene

estrogen receptor binding site associated antigen 9

Gene

solute carrier family 27 member 4

Gene

synaptotagmin 12

Gene

component of oligomeric golgi complex 4

Gene

ADP-ribosylhydrolase like 1

Gene

kelch domain containing 7A

Gene

apoptosis inhibitor 5

Gene

popeye domain cAMP effector 1

  • Gene

    transmembrane protein 276


  • Gene

    CXXC repeat containing interactor of PDZ3 domain


  • Gene

    estrogen receptor binding site associated antigen 9


  • Gene

    solute carrier family 27 member 4


  • Gene

    synaptotagmin 12


  • Gene

    component of oligomeric golgi complex 4


  • Gene

    ADP-ribosylhydrolase like 1


  • Gene

    kelch domain containing 7A


  • Gene

    apoptosis inhibitor 5


  • Gene

    popeye domain cAMP effector 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.